WishBone Medical, Inc. has announced its acquisition of the Turkish pediatric fixation device maker Response Ortho.
WishBone Medical, Inc. Acquires Response Ortho

Response Ortho has been in business for 14 years and is dedicated to increasing procedural efficiency and cost effective patient outcomes for the treatment of complex orthopedic conditions through the development of innovative, patented solutions for advanced fracture formation and bone deformity correction. The company has built a modern, high-tech manufacturing facility with access to an experienced engineering and technical labor force.
Response Ortho’s portfolio includes 30 pediatric orthopedic systems. Eighteen of these devices are cleared or approved for the U.S. market. The company is working on FDA clearance for the remaining products. Prior to its acquisition of Response Ortho, Wishbone Medical had 8 product systems.
WishBone Medical Chairman of the Board and CEO Nick Deeter said, “With the acquisition of Response Ortho, we are thrilled about our pediatric orthopedic product offerings. The combination of Response Ortho’s thirty product systems and WishBone’s eight product systems will give WishBone Medical the broadest product portfolio in pediatric orthopedics worldwide…. These pediatric orthopedic products can be delivered in sterile packed, procedural kits anywhere in the world, next day, to the surgeons that care for children.”
OTWasked Deeter why WishBone Medical chose to acquire Response Ortho. He explained, “When I compared our product development projects for the next two years, for implants designed for children, Response Ortho already had these same products being used in kids in six different countries outside the U.S. This acquisition moved WishBone Medical forward by a couple years and eliminated all our product development risk.”
Sehmuz Isin, CEO of Response Ortho, expressed his excitement at the acquisition. “We are excited that Response Ortho is now part of WishBone Medical. Our primary focus has been outside the U.S., and we will now be able to offer these innovative orthopedic product systems everywhere. Having more than 50 years of combined experience, Nick and I understand the unmet needs and will provide global solutions to children with orthopedic issues.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.